Deer River, MNNCT06028022Now EnrollingIRB Ready

Breast Cancer Clinical Trial in Deer River, MN

Access cutting-edge breast cancer treatment through this phase 2 clinical trial at a research site in Deer River. Study-provided care at no cost to qualified participants.

Sponsored by Mayo Clinic

Quick Self-Assessment

See if you qualify for this Deer River location

Preparing your pre-screening questions…

Expert Care in Deer River

Access breast cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related breast cancer treatment provided free

Apply for This Deer River Location

Check if you qualify for this breast cancer clinical trial in Deer River, MN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Deer River

    Convenient for MN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Deer River site if eligible
  4. 4Begin participation

About This Breast Cancer Study in Deer River

This phase II trial tests how well Reishi mushroom extract works in treating fatigue and/or joint/muscle pain (arthralgias/myalgias) in patients with breast cancer on aromatase inhibitors. Fatigue and arthralgias/myalgias are common symptoms in breast cancer patients taking aromatase inhibitors (AI). Given the long duration of AI treatment for some women (up to 10 years), these symptoms can significantly impact quality of life and premature discontinuation of AIs, a beneficial medication. Reishi

Sponsor: Mayo Clinic

Who Can Participate

Inclusion Criteria

Age ≥ 18 years
History of breast cancer, estrogen receptor positive (ER+), Her 2 positive or negative
Fatigue ≥ 4/10
Currently post-menopausal (as defined by National Comprehensive Cancer Network (version 4.2024), taking any aromatase inhibitor in the curative setting and planning to be on such for at least 8 weeks after registration. \[Patients on concurrent ovarian suppression (such as with leuprolide acetate, goserelin) are allowed\]; CDK 4/6 inhibitors abemaciclib, ribociclib ARE allowed
Prior treatment: last chemotherapy ≥ 90 days prior to randomization (if treated with chemotherapy)
On a stable dose of pain medications if pain medications are being regularly used. (i.e., no change in dosage in the past 30 days)
If on supplements, must be on stable dose with no plan to change; not on or planning any acupuncture or other specific supportive modalities for fatigue or AI arthralgias
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
White blood cell count (WBC) ≥ 3,000/mm\^3 (obtained ≤ 30 days prior to randomization)
Hemoglobin ≥ 10 g/dL (obtained ≤ 30 days prior to randomization)
Platelet count ≥ 100,000/mm\^3 (obtained ≤ 30 days prior to randomization)
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 30 days prior to randomization)
Alanine aminotransferase (ALT) or aspartate transaminase (AST) ≤ 1.2 x ULN (obtained ≤ 30 days prior to randomization)
Prothrombin time (PT)/activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN (obtained ≤ 30 days prior to randomization)
Negative pregnancy test done ≤ 7 days prior to registration, for persons on concurrent ovarian suppression only
Provide informed consent
Ability to complete questionnaires
Willing to return to enrolling institution during the active monitoring phase of the study
Patients who have had a recent surgery or procedure should be healed and cleared by their clinician and/or surgeon per local standards, prior to registration

Exclusion Criteria

Other known uncontrolled medical conditions causing fatigue such as untreated thyroid disease, depression, fibromyalgia, chronic fatigue syndrome, infection, autoimmune disease, or active/untreated hepatitis
Allergy to mushrooms
On anticoagulation medication or aspirin or having a known bleeding disorder
On any specific medication for fatigue (e.g., methylphenidate)
Metastatic cancer diagnosis (history of nodal metastases is allowed)
Chronic steroid use, unless on physiologic replacement doses
Current use of any medical mushrooms
On medications for diabetes
History of symptomatic hypotension
Taking CYP3A4, CYP2D6 sensitive substrates which can be located at the following link: https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems
Drugs which exhibit either \>20% inhibition or \>20% induction of CYP2E1 in vivo, such as: Acetaminophen, Dapsone, Enflurane, Halothane, Isoflurane, \& Theophylline
Taking olaparib
Any of the following because this study involves an agent that has unknown genotoxic, mutagenic and teratogenic effects:
Pregnant persons
Nursing persons
Persons on concurrent ovarian suppression who are unwilling to employ adequate contraception (e.g., hormonal methods, barrier methods, intrauterine device, abstinence)
Planned surgery or procedure during time on study and ≤ 14 days after last dose, due to bleeding risks

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Deer River?

Yes, this clinical trial (NCT06028022) has an active research site in Deer River, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Breast Cancer Treatment Options in Deer River, MN

If you're searching for breast cancer treatment options in Deer River, MN, this clinical trial (NCT06028022) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Deer River research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all breast cancer clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Deer River, MN

See all breast cancer clinical trials recruiting in Deer River — not just this study.

Browse Breast Cancer Trials in Deer River →

Browse More Trials by Condition

Breast Cancer TrialsTriple Negative Breast Cancer TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Deer River?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Deer River, MN